NPWT PRO vs KCI Ulta® NPWT and to Compare NPWT PRO vs NPWT PRO With Simultaneous Irrigation on Wound Healing

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-04-30

Study Completion Date

2020-06-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to assess the efficacy and economics of two NPWT (negative pressure wound therapy) branded devices of wound healing outcomes. It is also designed to assess the effectiveness of negative pressure and negative pressure with continuous irrigation on multiple parameters of wound healing. It is a single-center, open-label, active controlled, parallel-group trial that aims to determine the efficacy of Quantum with simultaneous irrigation in the treatment of diabetic foot ulcers. Specifically, eligible participants will be randomized to receive either PRO negative press therapy with simultaneous irrigation; or PRO negative pressure therapy without irrigation; or KCI Ulta negative pressure therapy. Outcomes will include rates of wound healing, time to closure, number of surgeries, length of stay, and days to heal.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Coupling Negative Pressure Wound Therapy With Instillation

NCT04677166

Wound Ulcer Burns

TERMINATED NA

Negative Pressure Wound Therapy: Are All Systems Alike?

NCT00590369

Wounds

TERMINATED PHASE3

Regulated Negative Pressure-Assisted Wound Therapy Device

NCT01603901

Negative-Pressure Wound Therapy

UNKNOWN NA

Study Comparing iNPWT Dressing and Devices Affect on Bioburden Levels and Skin Condition After Seven Days

NCT05559697

Skin Reaction to Mechanical, Thermal and Radiation Stimuli Skin Sensitisation

COMPLETED NA

A Comparative Study of Platelet-Rich Plasma and Normal Saline Dressings in the Treatment of Chronic Wounds (PRP-NS Wound T)

NCT06849232

Wound Healing

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subjects will be taken to the operating room for the initial debridement procedure of the wound. At the end of the procedure, subjects who continue to meet all inclusion and no exclusion criteria will be randomized in a 1:1:1 ratio to be treated with either PRO, PRO with simultaneous irrigation (PROI), or KCI Ulta NPWT. Prior to study initiation sealed prenumbered randomization envelopes will be provided to the research staff and used to obtain randomization assignment. Opening of the randomization envelope will occur intraoperatively at the conclusion of the initial surgical debridement of the wound and conformation of all eligibility requirements. Study staff will use the randomization number labels contained in the envelop. The number will become the subject ID. The assignment will be subjects randomized to PRO, PRO with simultaneous irrigation, or KCI Ulta NPWT.

The research staff will note treatment assignments on the intra operative randomization CRF and instruct the investigator. Treatment therapy wound dressings will be applied in the operating room or in the patient's room immediately after surgery per the investigators discretion, according to the manufacturer's recommendations. In order to ensure consistent study treatment, subjects will receive assigned treatment therapies within their study arm after the initial and any subsequent surgical debridements until the wound is deemed ready for closure or coverage by the Investigator. Subjects randomized to the PRO with simultaneous irrigation Treatment arm are the only subjects that will receive irrigation therapy at any time during the study treatment period. If irrigation therapy is discontinued, subjects in the Treatment arm will transition to PRO NPWT without irrigation. Subjects randomized to the PRO Control arm will receive NPWT only from the PRO therapy unit.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Partial-thickness Burn Ulcer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NPWT PRO without irrigation

Cardinal Health NPWT PRO system (K143016) continuous/intermittent vacuum-assisted drainage

Group Type ACTIVE_COMPARATOR

NPWT PRO without irrigation

Intervention Type DEVICE

NPWT PRO without irrigation.

NPWT PRO with Irrigation

Cardinal Health NPWT PRO system (K143016) continuous/intermittent vacuum-assisted drainage with simultaneous delivery of topical wound treatment solutions and suspensions over the wound bed (saline irrigant).

Group Type ACTIVE_COMPARATOR

NPWT PRO with irrigation

Intervention Type DEVICE

NPWT PRO with irrigation (saline)

KCI Ulta NPWT

KCI Ulta NPWT without irrigation.

Group Type ACTIVE_COMPARATOR

KCI Ulta

Intervention Type DEVICE

KCI Ulta NPWT without irrigation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NPWT PRO without irrigation

NPWT PRO without irrigation.

Intervention Type DEVICE

NPWT PRO with irrigation

NPWT PRO with irrigation (saline)

Intervention Type DEVICE

KCI Ulta

KCI Ulta NPWT without irrigation

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Cardinal Quantum NPWT PRO Cardinal Quantum NPWT PRO

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Presents with an existing chronic or traumatic wound, sub-acute or dehisced wound, partial-thickness burn, ulcer (such as a diabetic or pressure ulcer), flap or graft as diagnosed by a qualified and certified medical practitioner (M.D., D.O., or D.P.M)
* Wound presents with full thickness loss of epidermis and dermis
* The presentation of a wound that in the opinion of the investigators will require surgical debridement, and the wound is expected to be a good candidate for NPWT and eventual wound closure.
* ABI≥0.5 or toe pressures \>30 PVR/mmHg
* Subject is willing and able to abstain from partaking in any other form of treatment for his or her wound throughout the duration of his or her course of participation in the clinical study, other than the study procedures described herein.
* 18 years of age or older

Exclusion Criteria

* Does not present with an existing chronic or traumatic wound, sub-acute or dehisced wound, partial-thickness burn, ulcer (such as a diabetic or pressure ulcer), flap or graft, or a definitive diagnosis cannot be made, as diagnosed by a qualified and certified medical practitioner (M.D., D.O., or D.P.M)
* Wound does not present with full thickness loss of epidermis and dermis
* ABI\<0.5 or toe pressures \<30 PVR/mmHg
* Subject is not willing or is not able or it is not medically prudent for the subject to abstain from partaking in any other form of treatment for his or her wound throughout the duration of his or her course of participation in the clinical study, other than the study procedures described.
* Subject is unwilling or unable to use the NPWT device at home
* Active Charcot arthropathy
* Collagen vascular disease
* Scleroderma
* Non-enteric and unexplored fistula
* Necrotic tissue with eschar present after debridement
* General skin disorder in the area of the wound such as psoriasis or penicilitis
* Malnutrition (defined as BMI \<19)
* Hypercoagulable state based on documentation in their medical record
* Acute deep vein thrombosis
* Current active malignancy in the wound
* Current melanoma or history of melanoma at the wound
* Current active or history of invasive squamous cell carcinoma at the wound
* Sepsis (defined as positive blood culture with leukocytosis) and temperature \>101.5 at the time of screening
* Significant Hematologic disorders EXCLUDING anemia
* HIV
* Fever at screening \> 101.5
* Deep X-ray therapy
* Untreated bone or soft tissue infection (osteomyelitis)
* Any concomitant illness(es) or medical condition(s) that in the opinion of the investigator would render the subject not suited for study participation
* Subject is taking a regimen of any medication(s) in a significant enough dosage that may affect chronic wound healing, including corticosteroid, chemotherapeutic and non-steroidal anti-inflammatory (NSAID) medications
* Less than 18 years of age
* Developmental disability/significant psychological disorder that could impair the subject's ability to provide informed consent, participate in the study protocol or record study measures, including schizophrenia, bipolar disorder and psychiatric hospitalization within the last 2 years.
* Females currently pregnant or planning pregnancy during the course of intended participation in the study
* Active alcohol or substance abuse in the opinion of the investigator that could impair the subjects ability to provide informed consent, participate in the study protocol or record study measures.

Minimum Eligible Age

18 Years

Maximum Eligible Age

89 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No